Ostem Implant Expands Philadelphia Factory in the US... "HiOssen Production Capacity Increased by 58%"

Groundbreaking Ceremony for Osstem Implant's HiOssen Production Plant in the U.S. Subsidiary.
[Photo by Osstem Implant]

[Asia Economy Reporter Lee Gwan-joo] Osstem Implant announced on the 15th that it has completed the groundbreaking ceremony for the expansion construction of its U.S. subsidiary's production plant, the 'HIOSSEN Production Plant.' The completion is scheduled for August next year, and production at the new plant is expected to begin in September.

The HIOSSEN U.S. Production Headquarters, located in Philadelphia, plans to expand the existing facility of approximately 1,828㎡ (553 pyeong) by adding about 2,786㎡ (843 pyeong), resulting in a total production facility size of 4,614㎡ (1,396 pyeong). The expanded building will include additional installation of essential core equipment for implant production, such as CNC (Computer Numerical Control), blasting, and etching machines.

The HIOSSEN production plant currently produces an average of 180,000 sets per month this year, focusing on the high-end premium implant 'HIOSSEN' line and abutments. This volume accounts for 11% of the total annual production of Osstem Implant's three production plants in Korea, the U.S., and China. The U.S. Production Headquarters expects a 58% increase in production volume compared to the current output once the plant expansion is completed.

Angiltae, head of the U.S. Production Headquarters, stated, "Our key focus is not only to diversify the range of products such as digital products and increase production volume but also to strengthen manufacturing competitiveness and expand exports through quality improvement." He added, "We expect to establish a foundation to actively promote HIOSSEN products worldwide, recognizing their superior quality not only in the U.S. market but also in the European market, where certification requirements are stringent."

The cumulative sales of the U.S. subsidiary for the second quarter of this year increased by 47% year-on-year, combining domestic sales in the U.S. (19%) and export sales (28%). HIOSSEN products are exported to a total of 50 countries, including those where Osstem Implant's overseas subsidiaries and dealer networks operate. Among these, the European and Middle Eastern subsidiaries sell HIOSSEN products through their own dealer networks.

The premium product 'EK system' from HIOSSEN, which received final approval from the U.S. Food and Drug Administration (FDA) in January this year, is scheduled for official launch early next year. The company plans to secure market share for premium products mainly in the Chinese and Latin American markets, including Mexico. The U.S. Production Headquarters aims to achieve export sales of 70 billion KRW this year by expanding the range and scale of export items.